Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT-2 Inhibition and Cardiovascular Disease Metabolomics Study
2017-005136-41Phase 4Active
- Sponsor
- Fundación IMABIS
- Start
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Metabolomics changes in plasma and Metabolomics changes in urine. Started Oct 2018; status: active.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2017-005136-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-005136-41.